NEW YORK – With its web-based digital pathology platform, Tribun Health said that its whole-slide image management software offers labs workflow improvements with the ability to integrate its system ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.

NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate cancer test thanks to a recent approval from the New York State Department of ...

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...